U. Lee

发表

Predictive Biomarkers and Personalized Medicine PIK 3 CA , BRAF , andPTENStatus andBene fi t fromCetuximab in the Treatment of Advanced Colorectal Cancer — Results from NCIC CTG / AGITG CO . 17

P. Gibbs, N. Pavlakis, D. Tu, 2014 .

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

P. Gibbs, N. Pavlakis, D. Tu, 2013, Clinical Cancer Research.

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, J. Meharchand, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II multicenter open‐label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies

G. Pond, A. Oza, K. Swenerton, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

A. Tinker, N. Le, K. Swenerton, 2008, Gynecologic oncology.

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

A. Tinker, N. Le, K. Swenerton, 2008, Gynecologic oncology.

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

A. Oza, E. Eisenhauer, S. Ellard, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

The clinical impact of COVID-19 on patients with cancer in British Columbia: An observational study

S. Chia, C. McGahan, R. Woods, 2022, Heliyon.

Metastatic Small Bowel Adenocarcinoma Mimicking a Primary Ovarian Mucinous Tumour – Clinical, Radiologic, Pathologic and Molecular Correlation

G. Wang, C. Hughesman, U. Lee, 2022, International journal of surgical pathology.

BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, D. Tu, 2012 .

Survival Outcomes of Ewing Sarcoma and Rhabdomyosarcoma by High- versus Low-Volume Cancer Centres in British Columbia, Canada

C. Simmons, U. Lee, A. Smrke, 2023, Diagnostics.

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

E. Eisenhauer, A. Oza, S. Ellard, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185

E. Eisenhauer, A. Oza, S. Ellard, 2008 .